EcoDrugPlus

Serum Amyloid P-Component-Like

Ensembl ID : ENSSAUG00010002044
Gene Symbol: LOC115567643
2 Cross references
378 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSSAUG00010018501
Gene Symbol: LOC115566838
2 Cross references
354 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSSAUG00010009489
Gene Symbol: LOC115570704
2 Cross references
359 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSSAUG00010002029
Gene Symbol: LOC115567639
2 Cross references
382 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSSAUG00010018567
Gene Symbol: SI:DKEY-91M11.5
1 Cross references
196 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSSAUG00010013401
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSSAUG00010026725
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSSAUG00010022198
Gene Symbol: LOC115584851
2 Cross references
215 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSSAUG00010015810
Gene Symbol: SCN5LAB
1 Cross references
262 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSSAUG00010024161
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSSAUG00010016268
Gene Symbol: SCN4A
1 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSSAUG00010022650
Gene Symbol: SCN8A
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).